20th November 2018 – Can-Fite
BioPharma Limited issued an announcement, which is summarized as
Can-Fite BioPharma Limited announced that
Professor Josep Llovet, an experienced leader with deep background in liver
cancer research and development, has been commissioned by the Company to assist
in the analysis of the Phase II data that is anticipated during the first
quarter of 2019.
Professor Llovet is Founder and Director of the
Liver Cancer Program and Full Professor of Medicine at the Mount Sinai School
of Medicine, New York University (USA), and Professor of Research-ICREA in the
BCLC Group, Liver Unit, IDIBAPS-Hospital Clínic, University of Barcelona.
Professor Llovet has been President, Secretary and Founder of the International
Liver Cancer Association (ILCA) and Chairman of the European Clinical Practice
Guidelines of management of liver cancer (EASL-EORTC). A renowned key opinion
leader, Dr. Llovet has published more than 240 articles in peer-reviewed
journals, more than 50 chapters of books, and has delivered more than 500
lectures. He has devoted the past 20 years of his career studying the
pathogenesis and treatment of liver cancer.
“We believe his depth of experience both as
researcher and as medical practitioner in treatment of liver cancer will be
beneficial to Can-Fite. His insight and commitment to this field will be quite
helpful as we create a new approach for liver cancer therapy.” stated Can-Fite
CEO Dr. Pnina Fishman.
The original website link：